Site is Being Upgraded

A candy way to treat Non-alcoholic fatty liver disease: Sugar-based therapy for Non-alcoholic fatty liver disease (NAFLD): D-Mannose, a C-2 epimer of glucose, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 18/March/2018, 8.51 am

Rare Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors PTEN and PDCD4, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 18/March/2018, 8.35 am
March 18, 2018
A candy way to extend lifespan: Sugar-based Lifespan extension therapy: Erythritol, a sugar alcohol/non-caloric sugar/food additive, may increase life span, via up-regulation of its target gene BubR1, 18/March/2018, 9.14 am
March 18, 2018
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


From Research findings to Therapeutic opportunity:

This study suggests a small molecule-based therapy for NAFLD. D-Mannose, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “D-Mannose or its analogues, either alone or in combination with other drugs,” may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  D-Mannose decreases the expression of HMGCR

Figure 2. The chemical structure of D-Mannose

[easy_payment currency=”USD”]


 

 

 

 

 



Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does D-Mannose decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A candy way to treat Non-alcoholic fatty liver disease: Sugar-based therapy for Non-alcoholic fatty liver disease (NAFLD): D-Mannose, a C-2 epimer of glucose, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 18/March/2018, 8.51 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.